The present study was designed to investigate the effects of benzyloxicarbonyl-L-phenylalanyl-
alanine-fluoromethylketone (
Z-FA.FMK), an inhibitor of
cathepsin B on
lung injury that occurs concurrently with liver injury induced by D-
galactosamine/
tumor necrosis factor-alpha (D-GalN/
TNF-alpha). Four groups of BALB/c male mice were treated as follows: Group 1--mice receiving intravenous (iv)
injections of physiological saline; Group 2--administered with 8 mg/kg
Z-FA.FMK by iv injection; Group 3--mice treated with 700 mg/kg D-GalN and 15 microg/kg
TNF-alpha by sequential intraperitoneal (ip) injection; Group 4--treated with 700 mg/kg D-GalN and 15 microg/kg
TNF-alpha by sequential ip injection 1 h after administration with 8 mg/kg
Z-FA.FMK. Mice from Groups 3 and 4 were sacrificed 4 h after D-GalN/
TNF-alpha injections. The mice treated with D-GalN/
TNF-alpha showed lung damage; increased
TNF receptor-associated factor immunoreactivity, lipid peroxidation,
protein carbonyl content, and
lactate dehydrogenase activity; decreased
catalase,
superoxide dismutase, and
paraoxonase activities. Treatment with
Z-FA.FMK resulted in an improvement of these alterations in D-GalN/
TNF-alpha-administered mice. The apoptotic index of type-II pneumocytes was the almost same in the four study groups, but pneumocytes labeled with
proliferating cell nuclear antigen antibody was more numerous in Group 4 mice. Our results show that D-GalN/
TNF-alpha results in lung damage without induction of apoptosis. Treatment with
Z-FA.FMK stimulates proliferation of type-II pneumocytes and improves degenerative alterations in injured lung occurred with liver injury induced by D-GalN/
TNF-alpha.